Courtney Flaherty

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Kevin Kalinsky, MD, MS, FASCO, discusses how findings from SERENA-6 reinforce the importance of timely ESR1 testing in HR-positive breast cancer.

Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

The oncolytic virus candidate MVdeltaC has received FDA orphan drug designation for the treatment of patients with pleural mesothelioma.

Hope S. Rugo, MD, discusses key considerations and unanswered questions arising from the DESTINY-Breast09 trial in HER2-positive breast cancer.

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.

Nikhil Khushalani, MD, discusses the clinical potential of RP1 plus nivolumab in patients with PD-1–refractory melanoma as well as considerations regarding its use.

Nataliya Uboha, MD, PhD, underscores the crucial role of molecular profiling for guiding first-line treatment approaches in esophageal adenocarcinoma.

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Premal Thaker, MD, MS, discusses prior data supporting the ongoing investigation of IMNN-001 plus perioperative chemotherapy in ovarian cancer.

Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

The STAT3 inhibitor TT1-101 generated confirmed partial responses among patients with relapsed/refractory HCC and other solid tumors.

Justin Moser, MD, discusses efforts to develop a broader range of immunotherapy approaches for advanced melanoma after PD-1 inhibition.

Shannon Westin, MD, MPH, FACOG, contextualizes data from an exploratory biomarker analysis of the phase 3 DUO-E trial in pMMR recurrent endometrial cancer.

Treatment with eftilagimod alpha plus pembrolizumab produced a median OS of 17.6 months in the first line for patients with PD-L1–negative HNSCC.

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.

The AI-driven companion diagnostic device Ventana TROP2 (EPR20043) RxDx has received FDA breakthrough device designation in NSCLC.